FOLH1 and prostate carcinoma: The second-generation dual-labeled PSMA-914 compound was tested in the same year for the first preoperative PET/CT imaging and FGS in a patient with high-risk prostate cancer (Gleason score 9 [4 + 5] and initial PSA level 7 ng/mL).